Lv6
1914 积分 2022-12-13 加入
Phase 1 clinical trial of the ataxia telangiectasia and Rad3‐related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)
8天前
已完结
Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects
8天前
已完结
Immunohistochemical Evaluation of Schlafen 11 (SLFN11) Expression in Cancer in the Search of Biomarker-Informed Treatment Targets
9天前
已完结
Immunohistochemical Evaluation of Schlafen 11 (SLFN11) Expression in Cancer in the Search of Biomarker-Informed Treatment Targets
10天前
已完结
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers
10天前
已完结
The Novel ATR Inhibitor M1774 Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer Drugs
10天前
已完结
New Life of Topoisomerase I Inhibitors as Antibody–Drug Conjugate Warheads
10天前
已完结
TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor
10天前
已完结
Adaptive feedback signaling via the FAK/SRC pathway promotes KRAS G12C inhibitor resistance
11天前
已关闭
Fulzerasib plus cetuximab in first-line KRAS-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial
15天前
已完结
皖公网安备34019202002308
